https://doi.org/10.4081/jbr.2025.12728
Correlation of N-telopeptide of type 1 collagen and C-telopeptide of type 1 collagen in Iraqi women with breast cancer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 11 April 2025
Breast cancer is one of the most common cancers worldwide. It is a varied sickness that is the leading cause of cancer-related mortality in women. Prognostic biomarkers, N-telopeptide of type 1 collagen (NTX-1) and C-telopeptide of type 1 collagen (CTX-1), are undergoing increasing amounts of research; nevertheless, additional studies are required to enhance specificity and ascertain the true therapeutic utility of specific indications. The ELISA method was utilized to measure the levels of both (CTX- 1 and NTX-1). These markers were examined at the Oncology Teaching Hospital in the Medical City of Baghdad, in the serum of ninety women, fourty of whom were healthy and fifty of whom had the disease. The women's ages ranged from 40 to 60 years old. The statistical research showed that NTX-1 levels were significantly increased in the subjects with the disease, while CTX-1 did not reveal any discernible variation in comparison with healthy subject’s, with p-values (P≤0.0001). The best marker for breast cancer diagnosis, according to a Receiver Operating Characteristic curve analysis, is NTX-1. Our results indicate that serum NTX-1 has potential applications as a prognostic biomarker for bone metastases of several cancers, including breast cancer in Iraqi women.
Downloads
Alazzawi AA, Ghaloub AN, Yaaqoob LA. Investigating the antioxidant and apoptosis inducing effects of biologically synthesized silver nanoparticles against lymphoma cells in vitro. Iraqi J Sci 2023;4390-403. DOI: https://doi.org/10.24996/ijs.2023.64.9.9
Maged AG, Naeemah AL. Synthesis of new oxopyrimidine and cyanopyridine Derivatives containing the pyrimidine benzothiazole moiety with the evaluating their colon anticancer bioactivity. Iraqi J Sci 2023;30:3725-34. DOI: https://doi.org/10.24996/ijs.2023.64.8.1
Hussein MS, Al-Lami N. Anti-cancer and antioxidant activities of some new synthesized mannich bases containing an imidazo (2, 1-B) thiazole moiety. Iraqi J Sci 2022;30:4620-36. DOI: https://doi.org/10.24996/ijs.2022.63.11.1
Li J, Yang KL, Cai YT, et al. Quality assessment of global breast cancer screening guidelines. Zhonghua Liu Xing Bing Xue Za Zhi 2021;42:219-26.
Salman RA, Salman ZA. Evaluation of osteocalcin in serum women breast cancer in Iraq. Biochem Cell Arch 2021;21:4363-7.
Abdulameer AH, Hussein SZ. Assessment of oxidative stress parameters for some of Baghdad city fuel stations workers. Iraqi J Sci 2023;30:2669-80. DOI: https://doi.org/10.24996/ijs.2023.64.6.2
Psyrri A, Kalogeras KT, Wirtz RM, et al. Association of osteopontin with specific prognostic factors and survival in adjuvant breast cancer trials of the Hellenic Cooperative Oncology Group. J Transl Med 2017;15:1-11. DOI: https://doi.org/10.1186/s12967-017-1134-7
Wong GS, Rustgi AK. Matricellular proteins: priming the tumor microenvironment for cancer development and metastasis. Br J Cancer 2013;108:755-61 DOI: https://doi.org/10.1038/bjc.2012.592
Hamid GS, Allawi AA, Ghudhaib KK. Correlation of pentosidine with kidney diseases in Iraqi patients with diabetic nephropathy. Iraqi J Sci 2021;30:3436-42. DOI: https://doi.org/10.24996/ijs.2021.62.10.2
Li L, Shen X, Liang Y, et al. N-telopeptide as a potential diagnostic and prognostic marker for bone metastasis in human cancers: A meta-analysis. Heliyon 2023;9:e15980. DOI: https://doi.org/10.1016/j.heliyon.2023.e15980
Zhang W, Liu H, Jiang J, et al. Expression and significance of serum tumor markers in patients with bone metastasis of breast cancer. J Clin Med Pract 2022;26:43-7.
Wang M, Xia F, Wei Y, Wei X. Molecular mechanisms and clinical management of cancer bone metastasis. Bone Res 2020;8:30. DOI: https://doi.org/10.1038/s41413-020-00105-1
Haider MT, Saito H, Zarrer J, et al. Breast cancer bone metastases are attenuated in a Tgif1-deficient bone microenvironment. Breast Cancer Res 2020;22:1-6. DOI: https://doi.org/10.1186/s13058-020-01269-8
Jung K, Lein M, Stephan C, et al. Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. Int J Cancer Res 2004;111:783-91. DOI: https://doi.org/10.1002/ijc.20314
Lipton A, Smith MR, Fizazi K, et al. Changes in bone turnover marker levels and clinical outcomes in patients with advanced cancer and bone metastases treated with bone antiresorptive agents. Clin Cancer Res 2016;22:5713-21. DOI: https://doi.org/10.1158/1078-0432.CCR-15-3086
Coleman RE, Major P, Lipton A, et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005;23:4925-35. DOI: https://doi.org/10.1200/JCO.2005.06.091
Ferreira AR, Alho I, Shan N, et al. N-telopeptide of type I collagen long-term dynamics in breast cancer patients with bone metastases: clinical outcomes and influence of extraskeletal metastases. Oncologist 2016;21:1418-26. DOI: https://doi.org/10.1634/theoncologist.2015-0527
Li WB, Luo HJ, Wang P. Diagnostic value of ECT combined CYFRA21-1, NTX, BSP in lung cancer with bone metastasis. J Hubei Med Uni 2013;32:111-4.
Ulrich U, Rhiem K, Schmolling J, et al. Cross-linked type I collagen C-and N-telopeptides in women with bone metastases from breast cancer. Arch Gynecol Obst 2001;264:186-90. DOI: https://doi.org/10.1007/s004040000105
Liu F, Ke J, Song Y. Application of biomarkers for the prediction and diagnosis of bone metastasis in breast cancer. J Breast Cancer 2020;23:588. DOI: https://doi.org/10.4048/jbc.2020.23.e65
Chung YC, Ku CH, Chao TY, et al. Tartrate-resistant acid phosphatase 5b activity is a useful bone marker for monitoring bone metastases in breast cancer patients after treatment. Cancer Epidemiol Biomarkers Prev 2006;15:424-8. DOI: https://doi.org/10.1158/1055-9965.EPI-04-0842
Zulauf N, Brüggmann D, Groneberg D, Oremek GM. Expressiveness of bone markers in breast cancer with bone metastases. Oncology 2019;97:236-44. DOI: https://doi.org/10.1159/000500675
Brown J, Rathbone E, Hinsley S, et al. Associations between serum bone biomarkers in early breast cancer and development of bone metastasis: results from the AZURE (BIG01/04) trial. J Natl Cancer Inst 2018;110:871-9. DOI: https://doi.org/10.1093/jnci/djx280
Liu B, Zhao Y, Yuan J, et al. Elevated N-telopeptide as a potential diagnostic marker for bone metastasis in lung cancer: a meta-analysis. PLoS One 2017;12:e0187860. DOI: https://doi.org/10.1371/journal.pone.0187860
Zhang Y, Yi M, Cao J, et al. Serum cross-linked N-telopeptide of type I collagen for the diagnosis of bone metastases from solid tumours in the Chinese population: Meta-analysis. J Int Med Res 2016;44:192-200. DOI: https://doi.org/10.1177/0300060515600187
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.